http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2449818-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9c87d3df0e560e86392e20ecb1264630
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_878c66d036b83d0fcbbc39b0aab51696
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1e37bd625eab3599f9e0d1509c6e23d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30dea6b20b346161000a65faebbd5024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e848ec34a55c6dea8550abadf8c6579e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7746b5f36f6f455dd71d29443e699848
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M5-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-26
filingDate 2010-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2012-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_267430c5a67fc94df357c836aba70365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_322ddad46aa85ad6b77fa28b8f0c21a5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4340003193b6ecdce112f39602f7aa3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22dfe0c01a61a0135a3242e0a2053fe9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a48f364d84706ebc743a8586e89f554c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b6c4d16f90998097f831a57c19168ad
publicationDate 2012-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2449818-C1
titleOfInvention Method for treating hiv-infection
abstract FIELD: medicine. n SUBSTANCE: invention refers to medicine, namely diseases, and may be used for treating HIV-infection. That is ensured by blood purification from viruses, contaminated cells and associated microorganisms with the use of immunohemapheresis. The blood purification is preceded by 7÷10-day therapeutic course involving non-contact bioresonant exposure on patient's body 2 sessions a day each 20÷30 minutes. 15÷20 minutes before the beginning of each session, 2÷5 drops of magnetic active cluster organic iron with 5 ml of water is orally introduced to the patient. Each session is followed by intravenous introduction of 50÷70 ml of 10 % water mixtures of sodium thiosulphate and ascorbic acid in the ratio 4:1 by volume in 40÷60 seconds after mixing. After the therapeutic course, blood purification in an extracorporeal contour is applied in the patient. It is followed by a 5÷7-day pause, and the therapeutic course is repeated with blood purification for 2÷4 months. n EFFECT: method provides higher clinical effectiveness ensured by inactivation of infection agents, reduced body intoxication, prevented lipid peroxidation caused by decay products of infection agent cells. n 3 cl, 2 ex
priorityDate 2010-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2108101-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005242033-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2005138351-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24477
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23925
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54670067
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID447582325
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID12721
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491185
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID12721

Total number of triples: 40.